RecruitingPhase 3NCT07281079
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Studying Phelan-McDermid syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Neuren Pharmaceuticals Limited
- Intervention
- NNZ-2591(drug)
- Enrollment
- 160 enrolled
- Eligibility
- 3-12 years · All sexes
- Timeline
- 2025 – 2027
Study locations (2)
- Neuren PMS-301 Site#111, San Rafael, California, United States
- Neuren PMS-301 Site#109, Chevy Chase, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07281079 on ClinicalTrials.govOther trials for Phelan-McDermid syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07014020RB001 Gene Therapy Study in Children With SHANK3-related Phelan McDermid Syndrome (PMS)Peking University First Hospital
- RECRUITINGPHASE1, PHASE2NCT06662188JAG201 Gene Therapy Study in Children & Adults With SHANK3 HaploinsufficiencyJaguar Gene Therapy, LLC
- ACTIVE NOT RECRUITINGNCT02461420Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid SyndromeBoston Children's Hospital